Fresenius SE & Co KGaA (FRA:FRE) PT Set at €65.00 by Warburg Research

Share on StockTwits

Warburg Research set a €65.00 ($75.58) price target on Fresenius SE & Co KGaA (FRA:FRE) in a research note published on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also recently issued reports on FRE. Goldman Sachs Group began coverage on Taylor Wimpey in a report on Wednesday, June 12th. They set a buy rating for the company. JPMorgan Chase & Co. lifted their price objective on from GBX 385 ($5.03) to GBX 480 ($6.27) and gave the company an overweight rating in a report on Wednesday, July 3rd. DZ Bank reissued a sell rating on shares of ElringKlinger in a report on Wednesday, May 8th. Nord/LB set a €58.00 ($67.44) price objective on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Thursday, May 2nd. Finally, Independent Research set a €79.00 ($91.86) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a report on Friday, May 3rd. Nine investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of €58.61 ($68.15).

Shares of FRA FRE opened at €46.48 ($54.05) on Thursday. The firm’s fifty day moving average is €47.02. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Further Reading: The components of the Stochastic Momentum Index

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply